MOLECULAR MARKERS ASSOCIATED WITH THE RESPONSE TO THERAPY WITH EVEROLIMUS IN PATIENTS WITH RENAL CELL CARCINOMA
https://doi.org/10.21294/1814-4861-2016-15-2-42-47
Abstract
The purpose of the study was to evaluate the relationship between the levels of transcription factor, vascular endothelial growth factor (VEGF), serine/threonine-protein kinase (m-TOR), proteasome and calpain activities and the response to everolimus therapy in patients with disseminated renal cell carcinoma. Material and methods. The study included 18 patients with disseminated renal cell carcinoma. The expression of transcription and growth factors was studied using an immune enzymatic assay. Proteasome and calpain activities were evaluated using a fluorometric method. Results. Partial regression and stable disease were observed in 14 (78.8 %) of patients (tumor regression in 22.2 % of patients, stable disease in 56.6 % of patients). Disease progression occurred in 4 (22.2 %) of cases. The objective response to therapy with m-TOR inhibitor was observed in patients with high levels of NF-κB and HIF-1transcription factors, VEGF, VEGFR2 as well as with increased proteasome activity before treatment. Treatment response was also associated with low expression of phospho-m-TOR protein kinase. Conclusion. Additional predictive molecular markers of response to targeted therapy with evorolimus were revealed.
About the Authors
Z. А. Yurmazov
Tomsk Cancer Research Institute, 5, Kooperativny Street, 634009-Tomsk, Russia
Russian Federation
oncologist, General Oncology Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-код: 6342-8935.
Russian Federation
oncologist, General Oncology Department, Tomsk Cancer Research Institute (Tomsk, Russian Federation). SPIN-код: 6342-8935.
L. V. Spirina
Tomsk Cancer Research Institute, 5, Kooperativny Street, 634009-Tomsk, Russia
Siberian State Medical University, Tomsk
Russian Federation
MD, DSc, Senior Researcher, Laboratory of Tumor Biochemistry, Tomsk Cancer Research Center (Tomsk, Russian Federation). SPIN-code: 1336-8363.
Russian Federation
MD, DSc, Senior Researcher, Laboratory of Tumor Biochemistry, Tomsk Cancer Research Center (Tomsk, Russian Federation). SPIN-code: 1336-8363.
Е. А. Usynin
Tomsk Cancer Research Institute, 5, Kooperativny Street, 634009-Tomsk, Russia
Russian Federation
MD, PhD, Researcher, General Oncology Department, Tomsk Cancer Research Center (Tomsk, Russian Federation). SPIN-code: 1804-0292.
Russian Federation
MD, PhD, Researcher, General Oncology Department, Tomsk Cancer Research Center (Tomsk, Russian Federation). SPIN-code: 1804-0292.
I. V. Kondakova
Tomsk Cancer Research Institute, 5, Kooperativny Street, 634009-Tomsk, Russia
Russian Federation
MD, DSc, Head of Laboratory of Tumor Biochemistry, Tomsk Cancer Research Center (Tomsk, Russian Federation). SPIN-code: 9338-4149.
Russian Federation
MD, DSc, Head of Laboratory of Tumor Biochemistry, Tomsk Cancer Research Center (Tomsk, Russian Federation). SPIN-code: 9338-4149.
Е. М. Slonimskaya
Tomsk Cancer Research Institute, 5, Kooperativny Street, 634009-Tomsk, Russia
Siberian State Medical University, Tomsk
Russian Federation
MD, DSc, Professor, Head of General Oncology Department, Tomsk Cancer Research Institute; Professor of Department Oncology, Siberian State Medical University (Tomsk, Russian Federation). SPIN-code: 7763-6417.
Russian Federation
MD, DSc, Professor, Head of General Oncology Department, Tomsk Cancer Research Institute; Professor of Department Oncology, Siberian State Medical University (Tomsk, Russian Federation). SPIN-code: 7763-6417.
References
1. Alekseev B.Ya. Metastatic kidney cancer: Choice of first-line therapy // Oncourology. 2014. № 3. P. 43–48. DOI: http://dx.doi.org/10.17650/1726-9776-2014-10-3-43-48. [in Russian]
2. Kondakova I.V., Spirina L.V., Koval V.D., Shashova E.E., Choinzonov E.L., Ivanova E.V., Kolomiets L.A., Chernyshova A.L., Slonimskaya E.M., Usynin E.A., Afanas’ev S.G. Chymotrypsin-like activity and subunit composition of proteasomes in human cancers // Mol. Biol. Vol. 48 (3). P. 444–451. [in Russian]
3. Spirina L.V., Kondakova I.V., Usynin Y.A., Vintizenko S.I. Angiogenesis regulation in renal and bladder cancers // Siberian journal of oncology. 2008. № 4. P. 65–70. [in Russian]
4. Spirina L.V., Kondakova I.V., Usynin Y.A., Yurmazov Z.A. Expression regulation of transcription factors and endothelial growth factor by proteosomal system in patients with metastatic renal carcinoma // Journal of N.N. Blokhin Russian Cancer Research Center RAMS. 2012. Vol. 23, № 1. P. 27–32. [in Russian]
5. Atencio I.A., Ramachandra M., Shabram P., Demers G.W. Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines // Cell Growth Differ. 2000. Vol. 11 (5). P. 247–253.
6. Ben-Shahar S., Komlosh A., Nadav E., Shaked I., Ziv T., Admon A., DeMartino G.N., Reiss Y. 26 S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate // J. Biol. Chem. 1999. Vol. 274 (31). P. 21963–21972.
7. Dornbusch J., Zacharis A., Meinhardt M., Erdmann K., Wolff I., Froehner M., Wirth M.P., Zastrow S., Fuessel S. Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma // PLoS One. 2013. 8 (9): e76386. doi: 10.1371/journal.pone.0076386.
8. Fergelot P., Rioux-Leclercq N., Patard J.J. Molecular Pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer // Prog. Urol. 2005. Vol. 15 (6). P. 1021–1029.
9. Guertin D.A., Sabatini D.M. An expanding role for mTOR in cancer // Trends. Mol. Med. 2005. Vol. 11 (8). P. 353–361.
10. Heng D.Y., Xie W., Regan M., Warren M.A., Golshayan A.R., Sahi C., Eigl B.J., Ruether J.D., Cheng T., North S., Venner P., Knox J.J., Chi K.N., Kollmannsberger C., McDermott D.F., Oh W.K., Atkins M.B., Bukowski R.M., Rini B.I., Choueiri T.K. Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study // J. Clin. Oncol. 2009. Vol. 27 (34). P. 5794–5799. doi: 10.1200/JCO.2008.21.4809.
11. Heng D.Y., Xie W., Regan M.M., Harshman L.C., Bjarnason G.A., Vaishampayan U.N., Mackenzie M., Wood L., Donskov F., Tan M.H., Rha S.Y., Agarwal N., Kollmannsberger C., Rini B.I., Choueiri T.K. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study // Lancet Oncol. 2013. Vol. 14 (2). P. 141–148. doi: 10.1016/S1470-2045(12)70559-4.
12. Juvekar A., Manna S., Ramaswami S., Chang T.P., Vu H.Y., Ghosh C.C., Celiker M.Y., Vancuriva I. Bortezomib induces nuclear translocation of IkBα resulting in gene-specific suppression of NF-kB-dependent transcription and induction of apoptosis in CTCL // Mol. Cancer Res. 2011. Vol. 9 (2). P. 183–194. doi: 10.1158/1541-7786.MCR-10-0368.
13. Keefe S.M., Nathanson K.L., Rathmell W.K. The molecular biology of renal cell carcinoma // Semin. Oncol. 2013. Vol. 40 (4). P. 421–428. doi: 10.1053/j.seminoncol.2013.05.006.
14. Kohli V., Gao W., Carlos A., Clavien P.A. Calpain is a mediator of preservation-reperfusion injury in ratliver transplantation // Proc. Natl. Acad. Sci. USA. 1997. Vol. 94 (17). P. 9354–9359.
15. Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., Mazumdar M. Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma // J. Clin. Oncology. 2004. Vol. 22 (3). P. 454–463.
16. Na X., Wu G., Ryan C.K., Shoen S.R., di’Santagness P.A., Messing E.M. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxiainducible factor-1 alpha expression in renal cell carcinomas // J. Urol. 2003. Vol. 170 (2 Pt 1). P. 588–592.
17. Sandmann S., Prenzel F., Shaw L., Schauer R., Unger T. Activity profile of calpains I and II in chronically infarcted rat myocardiuminfluence of the calpain inhibitor CAL 9961 // Br. J. Pharmacol. 2002. Vol. 135 (8). P. 1951–1958.
18. Shida T., Kishimoto T., Furuya M., Nikaido T., Koda K., Takano S., Kimura F., Shimizu H., Yoshidome H., Ohtsuka M., Tanizawa T., Nakatani Y., Miyazaki M. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors // Cancer Chemother. Pharmacol. 2010. Vol. 65 (5). P. 889–893. doi: 10.1007/s00280-009-1094-6.
19. Spirina L.V., Kondakova I.V., Choynzonov E.L., Chigevskaya S.Y., Shishkin D.A., Kulbakin D.Y. Expression of vascular endothelial growth factor and transcription factors HIF-1 and NF-κB expression in squamous cell carcinoma of head and neck; association with proteasome and calpains activity // J. Cancer Res. Clin. Oncol. 2013. Vol. 139 (4). P. 625–633. doi: 10.1007/s00432-012-1366-0.
20. Storr S.J., Carragher N.O., Frame M.C., Parr T., Martin S.G. The calpain system and cancer // Nat. Rev. Cancer. 2011. Vol. 11 (5). P. 364–374. doi: 10.1038/nrc3050.
21. Wu W.K., Volta V., Cho C.H., Wu Y.C., Li H.T., Yu L., Li Z.J., Sung J.J. Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells // Biochem. Biophys. Res. Commun. 2009. Vol. 386 (4). P. 598–601. doi: 10.1016/j.bbrc.2009.06.080.
22. Yue C.X., Ma J., Zhou H.J., Tang Q.L., Li L.L., Bi F., Xue Y. The effect of RhoA and proteasome inhibitor MG132 on angiogenesis in tumors // Sichuan Da Xue Xue Bao Yi Xue Ban. 2011. Vol. 42 (4). P. 445–450.
Review
For citations:
Yurmazov Z.А., Spirina L.V., Usynin Е.А., Kondakova I.V., Slonimskaya Е.М. MOLECULAR MARKERS ASSOCIATED WITH THE RESPONSE TO THERAPY WITH EVEROLIMUS IN PATIENTS WITH RENAL CELL CARCINOMA. Siberian journal of oncology. 2016;15(2):42-47. (In Russ.) https://doi.org/10.21294/1814-4861-2016-15-2-42-47
Views:
693
Email this article 
